Investigation of Therapeutic Drug Monitoring of Tacrolimus in Different Age Groups: Results from a Turkish Nationwide Study
Letters in Drug Design and Discovery, cilt.20, sa.6, ss.718-723, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 20 Sayı: 6
- Basım Tarihi: 2023
- Doi Numarası: 10.2174/1570180819666220825122534
- Dergi Adı: Letters in Drug Design and Discovery
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, Chemical Abstracts Core
- Sayfa Sayıları: ss.718-723
- Anahtar Kelimeler: Tacrolimus, elderly, big data, drug analysis, drug monitoring, optimum immunosuppression
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: The blood level of tacrolimus (TAC) used for post-transplant immunosuppression should be within the therapeutic index. Geriatric individuals may be at risk of organ rejection because, in this age group, routine drug use is usualy disrupted, and the bioavailability of aging-related drugs is decreased. Objective: The aim of this study was to analyze the age-related variability of blood TAC levels in patients in Turkey.Methods: In this study, 697,616 patients who underwent TAC measurement in the laboratories of public, private, and university hospitals between 2018 and 2020 were identified from the Health-net database of the Ministry of Health. The results of patients aged ≥65 years were compared with those of patients aged<65 years. The differences between the sexes in the same age group were also examined. Data from the Turkish Ministry of Health National Electronic Database were used to design a multicenter retrospective cohort study.Results: The study included 697,616 patients. The mean TAC concentration was 7.2 ± 6.25 ng/mL for al the patients, 7.13 ± 6.7 ng/mL for the female patients, and 7.24 ± 5.96 ng/mL for the male patients. A statisticaly significant difference in TAC concentration was found between men and women in the general population. Groups aged ≥65 years were compared among themselves. A statisticaly significant decrease in TAC concentration was found only in the age group of 75–79 years (5.63 ± 4.09 ng/mL) of women compared with the men. In al other age groups, the TAC levels of the men were lower. Conclusion: The proportion of patients with TAC concentrations lower than the therapeutic index was higher in the groups aged ≥65 years. Thus, patients aged ≥65 years may be at risk of organ rejection, as optimum immunosuppression cannot be achieved. In these patients, more frequent drug monitoring and providing training to ensure the compliance of the patient and the patient's relatives in the use of TAC may be recommended.